Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of AK109 + cadonilimab + paclitaxel versus placebo + paclitaxel after failure of first-line PD-(L)1 inhibitor plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma
CTR20241225Phase 3Active
- Sponsor
- Kangrong Dongfang
- Start
- Jun 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pulocimab, cadonilimab, paclitaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Kangrong Dongfang. Started Jun 2024; status: active.
02
Drugs
pulocimabcadonilimabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20241225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241225.